The pharmaceutical and biotech sector is being reshaped by GLP-1 obesity drugs, supply chain reshoring, and intensifying competition between global pharma giants. Our coverage tracks the clinical pipelines, manufacturing buildouts, and valuation dynamics that matter most for healthcare investors.
Deep dive into oral Wegovy, clinical trial comparisons, China market expansion, manufacturing capacity, and who wins the GLP-1 race in 2026.
Read moreIn-depth analysis of pharmaceutical supply chain restructuring driven by tariff escalation, national security reclassification, and $100B+ in corporate reshoring commitments.
Read moreIn-depth comparison of the two pharmaceutical giants dominating the obesity and diabetes treatment market with breakthrough GLP-1 drugs.
Read moreBMY trades at its cheapest valuation in a decade. 6.7x forward P/E, 5.3% dividend yield, $13–15B FCF, and an $11B BioNTech oncology deal. Entry $45–$48. Target $55–$65.
Read moreTwo data events knocked AMGN 20% off its highs. At 14.3x forward earnings, the market assigns zero value to an obesity drug with 20% weight loss at 52 weeks, no plateau, and monthly dosing. Entry $...
Read more